DRREDDY stock news on Anadi Algo News

Monday, June 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|63 matching stories

DRREDDY Share Price, Latest News & Sentiment

Latest AI-analyzed news for DRREDDY, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

DRREDDY News Today

Large-cap stock hub

The banking sector is currently facing mixed signals, with some reports indicating a boost to the Indian stock market from banking, while others highlight potential future risks like a '₹ 60,000 Crore Time Bomb' starting in 2027. This makes selective investing within the sector crucial.

Coverage
63
recent stories
Sources
5
distinct publishers
Bias Split
26 bullish / 17 bearish
10 neutral stories
Window
89d
recent coverage span
Saved Quote Snapshot

DRREDDY

Last Updated
23 May 2026
Price
NA
NA
52W Range
NA - NA
exchange snapshot
PE / VWAP
PE NA
VWAP NA
Trend Read
mixed
EMA stack mixed
Business Context
Industry: NA
Sector Trail: NA
Listing Date: NA
Market Structure
F&O Eligible: No
Indices: NA
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Non-Consolidated results
What This Quarter Says

DRREDDY's latest filing shows a revenue of Rs 5015.0 crore and a profit of Rs 849.4 crore. This filing is on record, but we don't have previous quarter data to compare if performance improved or weakened. These numbers show how much money the company made and kept, which is important for understanding its financial health.

Revenue
Rs 5,015 cr
down 40.2% vs previous filing
Profit
Rs 849.4 cr
down 39.3% vs previous filing
EPS / Finance Cost
EPS 10.2
Finance cost Rs 43.3 cr
Filing Context
Filed 24 Jan 2025, 7:28 pm
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 5,015 cr, down 40.2% vs previous filing.
  • Profit this quarter: Rs 849.4 cr, down 39.3% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 10.2.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

DRREDDY FAQ

Why is DRREDDY in the news right now?

DRREDDY has appeared across 63 recent stories from 5 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is DRREDDY coverage bullish or bearish right now?

DRREDDY coverage is currently leaning bullish, with 26 bullish, 17 bearish, and 10 neutral analyzed stories in the recent window.

Which themes are moving with DRREDDY?

Recent DRREDDY coverage is clustering around Pharmaceuticals and Healthcare. Related names showing up alongside DRREDDY include SUNPHARMA, LUPIN, CIPLA.

How should I use this DRREDDY news page?

Use this page as a coverage hub for DRREDDY: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use DRREDDY coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Given the recommendation for banks, focus on large-cap private and public sector banks with strong asset quality and stable NIMs, considering potential long-term value despite short-term headwinds. Maintain strict stop-losses.|Quick check: HDFCBANK bearish bias (-0.7% 1d), ICICIBANK neutral (+0.6% 1d).
et_markets14 days ago

These 7 stocks reported declining EPS for 4 straight quarters

The news highlights specific profitability challenges within large-cap companies, which can influence broader market sentiment and sector performance. Persistent EPS decline suggests fundamental issues that may not be easily resolved.

Maintain a cautious stance on the mentioned stocks and their respective sectors; consider short-term bearish trades or avoiding long positions until a clear turnaround in profitability is evident.|Quick check: DRREDDY neutral (+0.2% 1d), GAIL bullish bias (-0.2% 1d).
et_markets20 days ago

Market Wrap: Sensex falls 479 points, Nifty below 23,950 as bank stocks falter; small, midcaps shine

The banking sector's underperformance is critical as it holds significant weight in benchmark indices. Geopolitical events impacting oil prices can directly affect Indian banks through inflation and interest rate expectations.

Maintain a cautious bias on banking stocks; consider short-term bearish positions or hedging strategies, while selectively looking for opportunities in resilient midcap and smallcap segments.|Quick check: HDFCBANK neutral (-0.9% 1d), ICICIBANK bullish bias (-1.0% 1d).

Latest DRREDDY Stock Coverage

Maintain a cautious bias on Indian pharma stocks with high exposure to branded oncology drugs, looking for signs of strategic adaptation or pricing pressure.|Quick check: DRREDDY neutral (oversold), SUNPHARMA bullish bias (overbought).
Maintain a bullish bias on Indian pharmaceutical stocks, especially those with strong API and formulation capabilities.|Quick check: SUNPHARMA bullish bias (+2.1% 1d), DRREDDY bullish bias (overbought).
Consider long positions in Dr. Reddy's and other identified stocks, with confirmation from price action and volume.|Quick check: DRREDDY bullish bias (overbought), NIFTY neutral.
Market has likely priced this in; maintain overweight on export-linked IT/pharma (TCS, INFY, SUNPHARMA) and underweight firms with high unhedged USD debt.
Market has likely priced this in post Q4 results; prefer India-focused pharma (Mankind, JB Chem) over US-heavy names like Cipla, DRREDDY, ZYDUSLIFE on rallies.
Bullish medium-term for export-linked names; accumulate pharma (SUNPHARMA, DRREDDY) and engineering (BHARATFORG, LT) on dips — immediate move likely priced in.
Market has likely priced in the headline already; only add to pharma/FMCG exports on fresh evidence of order growth, margin expansion and customs/export volume acceleration, else stay selective.
Market has likely priced this in; wait for official feedstock-allocation updates, and only add selective long bias in quality large-cap pharma on confirmation of normalized supply, with tight stop discipline on any renewed input warning.
Bullish for industrial sectors like steel, pharma, and polymers; consider long positions in companies with high LPG consumption.
Market has likely priced in general positive sentiment; focus on specific policy announcements for actionable trades in IT and Pharma.
Maintain a cautious stance on Indian equities, particularly in import-dependent sectors and those with significant export exposure, and consider defensive plays.
Market has likely priced in the initial sentiment; however, monitor policy developments and investment announcements in API manufacturing for long-term bullish plays on domestic pharma and chemical companies.
Market has likely priced this in, but long-term investors should consider Indian pharma stocks with strong domestic manufacturing and R&D capabilities for sustained growth.
Market has likely priced this in given the article age; however, monitor pharma and logistics stocks for long-term growth potential from improved export infrastructure.
Monitor pharmaceutical stocks with exposure to weight-loss drugs for potential short-term volatility due to regulatory uncertainty.
Focus on large-cap Indian pharma companies and IT service providers with strong AI capabilities, as they are poised for long-term growth from this technological shift.
Maintain a neutral stance on major Indian generic pharma stocks, but monitor for any policy shifts that could extend US tariffs to generics.
Given the article's age, the market has likely priced in initial reactions; however, monitor US trade policy developments for lingering effects on Indian pharma exporters.
Bullish for Indian pharma and healthcare stocks; monitor companies with potential to enter or expand in the weight-loss drug and wellness market.
Maintain a cautious stance on Indian pharma stocks due to persistent supply chain risks, despite government intervention.
Bearish for Indian pharma companies with GLP-1 agonist pipelines; monitor competitive pricing actions and margin impacts.
Bearish for Indian pharmaceutical companies with exposure or potential entry into the semaglutide market; anticipate margin pressure due to aggressive pricing.
Monitor Indian pharmaceutical companies with strong R&D and manufacturing capabilities for generic semaglutide, as initial price wars may give way to volume-driven growth.
Monitor Indian pharmaceutical companies with significant GLP-1 drug pipelines for potential short-term revenue adjustments due to increased regulatory friction.
Monitor government actions on chemical allocation; potential for short-term volatility in pharma stocks, but long-term impact depends on resolution.
Bearish for Indian pharma companies with significant diabetes/obesity portfolios; consider reducing exposure or shorting specific names.
Market has likely priced this in given the article age; however, monitor for specific company announcements regarding IP disputes, especially in pharma and IT.
Consider hedging import-heavy portfolios and look for opportunities in export-oriented IT and Pharma stocks, but be mindful of broader market volatility.
Market has likely priced this in; however, maintain a cautious stance on import-heavy sectors and consider hedging strategies, while export-oriented IT and Pharma stocks may see continued support on dips.
Prepare for Rupee depreciation; consider hedging import exposure and look for opportunities in export-oriented sectors like IT and Pharma.
Monitor Indian IT service providers for increased deal flow in life sciences AI, and Indian pharma for strategic AI adoption announcements.
Consider accumulating Indian pharmaceutical stocks with strong metabolic therapy pipelines, as the GLP-1 market shift presents a significant long-term growth opportunity.
Market has likely priced this in; monitor major pharma companies for any specific announcements regarding GLP-1 drug compliance or market strategy shifts.
Bearish for import-heavy sectors like OMCs and auto; bullish for IT and pharma exporters. Consider hedging strategies for import-dependent businesses.
Bearish for Dr. Reddy's in the near term due to legal overhang; watch for similar actions against other generic players entering the weight-loss drug market.
Market has likely priced this in; however, continued rupee depreciation and high crude prices warrant caution for import-heavy sectors and could support IT/Pharma exporters.
Consider hedging against Rupee depreciation; favor export-oriented sectors like IT and Pharma, while being cautious on import-heavy sectors and OMCs.
Bullish for Indian generic pharma companies; consider long positions in major players with strong domestic presence.
Market has likely priced this in; however, continue to monitor crude oil prices and global geopolitical developments for sustained rupee weakness, favoring IT and Pharma exporters while being cautious on oil marketing companies.
While the article is old, the underlying theme of India's potential in pharma remains; consider long-term accumulation in quality Indian pharma and CRO stocks on dips.
Monitor regulatory developments in clinical trial approvals; positive reforms could signal long-term bullish sentiment for Indian pharma stocks.
Consider long positions in Indian pharmaceutical companies with strong generic pipelines, as the obesity drug market offers significant growth potential.
Consider a bullish bias for Alkem Laboratories due to its strategic entry into the high-growth semaglutide market, while monitoring competitive responses from other pharma majors.
Bullish for Indian pharmaceutical companies; consider long positions in major generic drug manufacturers with strong R&D and manufacturing capabilities.
Traders should monitor Indian pharmaceutical companies for their generic semaglutide launch plans and assess potential pricing strategies, as increased competition could compress margins.
Monitor Q1/Q2 FY27 results of major Indian pharma players for early indications of market share and pricing power in the generic Semaglutide segment.
Monitor NATCOPHARM for potential upside due to market share gains, while watching for competitive pressure on other diabetes drug manufacturers.
Focus on export-oriented Indian companies, particularly in IT, textiles, and pharmaceuticals, as they stand to benefit from enhanced market access to the UK and EU.
Consider hedging import-heavy portfolios and look for opportunities in export-oriented IT and Pharma sectors, while monitoring RBI's intervention stance.
Consider long positions in large-cap, compliant pharmaceutical companies as regulatory standardization reduces operational risks and improves market access.
Monitor regulatory developments in the Indian pharmaceutical sector; potential for increased scrutiny on drug marketing could create headwinds for pharma stocks.
Consider long positions in Indian generic pharmaceutical companies and hospital chains, as the obesity treatment market is set for significant expansion.
Monitor government's response to the SEZ import proposal; a positive decision could provide a cost advantage for SEZ-based manufacturers, particularly in solar, pharma, and chemicals.
Market has likely priced this in, but continue to monitor crude oil prices and global geopolitical developments for sustained rupee weakness, favoring IT and Pharma exporters while being cautious on oil importers and companies with high import dependence.
Consider accumulating quality private bank, IT, and manufacturing stocks on dips for long-term gains, as valuations appear attractive post-correction.
Bullish for Indian pharma and healthcare exporters; consider long positions in companies with strong export footprints.